Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

PTC Therapeutics partners with Novartis for its PTC518 Huntington's program in a deal valued up to $2.9 billion, including ...

But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...

Despite the “unfortunate” failure, William Blair analysts do not believe that the utreloxastat readout will heavily affect ...

PTC Therapeutics (NASDAQ:PTCT) said a Phase 2 placebo-controlled study of its ALS drug candidate utreloxastat failed to meet ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...

The announcement means the company will be pulling the plug on the CardinALS trial after its amyotrophic lateral sclerosis ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...

PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...

Utreloxastat was demonstrated to be safe and well tolerated in the CardinALS trial. However, due to the lack of efficacy and biomarker signal, further development is not planned at this time. PTC ...

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease progression on the composite ...